Skip to main content
OpenTrials
Completed

NCT Number: NCT01768065

Nasal Expiratory Positive Airway Pressure for the Treatment of Pediatric Obstructive Sleep Apnea Syndrome

This study will evaluate effectiveness and adherence of the nasal expiratory positive airway pressure (NEPAP) device as an an alternate therapy for children with Obstructive Sleep Apnea Syndrome (OSAS). NEPAP is currently approved for use only in adults.

Completed

Looking for future studies?

Notify Me

Key information

Age range

5 year–16 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Early Phase 1

Primary location

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, 19104, United States

About this study

The nasal expiratory positive airway pressure (NEPAP) device has been used to treat OSAS in adults. A disposable device is placed in each nostril at night and attached with adhesive. The device acts as a one-way valve, during inspiration the valve opens, with negligible resistance to flow. During expiration, the valve closes and airflow is directed through small air channels, increasing resistance. The increased resistance helps to maintain the upper airway pressure during the critical end-expiratory period when the upper airway has been found to be most narrow in the breaths preceding an apnea event. In contrast to Continuous Positive Airway Pressure (CPAP) which provides positive pressure during both inspiration and expiration, NEPAP creates pressure during expiration. NEPAP is a potential alternative therapy which is less cumbersome than CPAP and may increase adherence.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects age 5-16 years (note: Due to the size of the devices, it is expected that most children will be at least 8 years old, but a few may be younger. Subjects will be evaluated in clinic to fit for size and habituate to the device)
  • OSAS (AHI > 5/hr)
  • Subject has had adenotonsillectomy or is not a candidate for adenotonsillectomy
  • Subject is non-adherent to CPAP or is seeking an alternative therapy
  • Tolerance of NEPAP device during a daytime session
  • Parental/guardian permission (informed consent) and if appropriate, child assent.

Exclusion criteria

  • Severe developmental delay thought to involve a high risk of aspiration
  • Family does not understand English well enough to perform the standardized, validated questionnaires.
  • Age >16 years since results may be similar to adult studies in these older patients.
  • Severe breathing disorder (including respiratory muscle weakness, bullous lung disease, bypassed upper airway, pneumothorax, pneumomediastinum)
  • Severe heart disease (including heart failure)
  • An acute upper respiratory (including nasal, sinus or middle ear) inflammation or infection or perforation of the ear drum

Subjects that do not meet all of the enrollment criteria will not be enrolled. Any violations of these criteria will be reported in accordance with Institutional Review Board (IRB) Policies and Procedures.

Study members will not recruit females who are known to be pregnant. However, if a subject becomes pregnant during the study, we will continue to use the device. Pregnancy is not an exclusion criterion as positive airway pressure therapy does not harm the pregnant woman or fetus.

Treatment and study plan

Nasal Expiratory Positive Airway Pressure Device

Device

assigned to Nasal Expiratory Positive Airway Pressure arm

Placebo sham

Device

Primary outcomes

  1. Apnea hypopnea index

    Time frame: Approximately one week

    The apnea hypopnea index during polysomnography will be compared between the active device and the placebo nights

Secondary outcomes

  1. Adherence using daily logs

    Time frame: One month

    Adherence with using devices will be determined by daily logs and collecting used devices

Other outcomes

  1. Quality of life

    Time frame: One Month

    The Pediatric Quality of Life (PedsQL) score will be compared at baseline and after one month of device usage

Sponsors and collaborators

Lead sponsor

Children's Hospital of Philadelphia

Other

Registry information

Important dates

Study start
2012
Primary completion
2013
Study completion
2013
First posted
Jan 15, 2013
Registry last updated
Sep 10, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.